Indications
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Composition
- Active substance
- brodalumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kyntheum
- Active substance
- brodalumab
- ATC code
- L04AC12
- Therapeutic area
- Psoriasis
- Marketing authorisation holder
- LEO Pharma A/S
- Status
- Authorised
- EU authorisation
- 17 Jul 2017